MultiOmic Health and Mesh Bio to use AI to develop precision medicines

Andrew Wu, Co-Founder and Chief Executive Officer at Mesh Bio

MultiOmic Health, an artificial intelligence-enabled drug discovery company, and Mesh Bio, a digital health startup transforming chronic disease management through predictive analytics, announced their partnership to conduct an observational clinical study on patients with chronic metabolic disease and increased risk of complications such as chronic kidney disease.

What does the partnership mean to patients in Asia?

The partnership will provide access to data from patient populations in Asia that have historically been underrepresented in chronic metabolic disease studies. Mesh will collaborate with its network of healthcare provider customers to recruit patients for the study.

MultiOmic will generate genomic, proteomic, metabolomic and other omics data from anonymized body fluid samples. These will be combined with anonymized data from clinical and diagnostic tests to build a rich multi-omics dataset and derive AI-based computational biology models. This will enable both firms to progress their R&D programs to develop products that will transform the lives of patients with metabolic syndrome-related conditions.

They will also conduct collaborative projects to enhance patient stratification for other biopharma and medtech firms’ clinical-stage R&D. Metabolic syndrome-related conditions like type 2 diabetes mellitus (T2D), chronic kidney disease (CKD), atherosclerotic cardiovascular disease (ASCVD), non-alcoholic fatty liver disease (NAFLD) and polycystic ovary syndrome (PCOS) arise from a common set of risk factors present in half the world’s adult population.

These age-related conditions can lead to serious consequences, including heart attack, stroke, blindness, nerve damage, foot amputation, kidney dialysis and liver failure. Prior to the COVID-19 pandemic, they accounted for half the world’s deaths and nearly US$ 2 trillion in global healthcare spending. This burden will be further exacerbated by the pandemic.

A significant proportion of COVID-related hospitalizations and fatalities arose in patients with metabolic syndrome conditions and recent research studies have also indicated that COVID survivors have an increased risk of being diagnosed with T2D3 and CKD4 in the future.

What were the executives’ thoughts on the partnership?

“This deal gives us access to a population base in Asia exhibiting increasing prevalence of metabolic syndrome-related conditions,” said Robert Thong, Co-Founder and CEO, MultiOmic.

“We are delighted to collaborate with Mesh Bio as a like-minded and strategic partner working with healthcare providers that have many patients in our target chronic medical conditions. Our product development programs and technical teams also complement each other.”

“Longitudinal multi-omics data combined with deep clinical phenotyping is essential to developing transformative therapeutics and diagnostics in chronic multi-factorial diseases,” said Angeli Möller, PhD, Vice-Chairperson and co-founder of the Alliance for Artificial Intelligence in Healthcare, the advocacy firm for applying AI solutions to improve patient lives.

“In contrast to most of the historical research for these diseases that has relied on Caucasian patients, this deal will generate new and much needed insights specific to populations in Asia.”

“Mesh Bio is committed to driving clinical interventions in the management of chronic metabolic disease to improve patient outcomes. Our vision is for holistic patient assessment, powered by analytics on fullstack biology,” said Andrew Wu, Co-Founder and CEO of Mesh.

“We are excited to partner with MultiOmic Health on this study for patients in Asia. Their therapeutic development programs for metabolic disease intervention have deep synergies with Mesh Bio’s mission to develop digital care delivery solutions for these diseases.”